p53-Tumor Suppression

The vast majority of p53-regulated genes are induced in response to various stress signals and are responsible for maintaining genetic stability, DNArepair, regulation of crucial cell-cycle check points, and finally induction of apoptosis. The activity of p53 is tightly controlled by two major negative regulators including murine double minute 2 (MDM2; EC 6.3.2.19) and 4 (MDM4 or MDMX) proteins. Human MDM2 and MDMX are structurally related and contain three well-conserved domains: an N-terminal domain (responsible for p53 binding), a zinc-finger domain (function largely unknown) and a C-terminal RING domain (responsible for formation of homo- and heterodimers). Additionally, the RING domain of MDM2 confers E3 ubiquitin ligase activity. Concentration/activity of p53 is kept at low level in unstressed cells. This is accomplished by three parallel mechanisms mediated by MDM2 and/or MDMX. First, MDM2 and MDMX bind the N-terminal transactivation domain (TAD) of p53, preventing thereby its interaction with the transcription machinery and resulting in the inhibition of p53-responsive gene expression. Second, MDM2/X proteins export p53 outside the nucleus into the cytoplasm where it can no longer activate transcription. Finally, MDM2 marks p53 for proteasomal degradation[1]. Many tumors overproduce MDM2 to impair p53 function. Therefore, restoration of p53 activity by inhibiting the p53–MDM2 binding represents an attractive novel approach to cancer therapy[2].


[1] K. Zak et al. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present). Exp. Opin. Ther. Pat. 2013, 23, 425-448.
[2] B.T. Vu, L. Vassilev. Small-Molecule Inhibitors of the p53-MDM2 Interaction. Curr. Top. Microbiol. Immun. 2011, 348, 151-172.

Items 1 to 15 of 72 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Axon ID Name Description From price
2138 ZCL 278 Cdc42 GTPase inhibitor, targeting Cdc42–ITSN interaction €105.00
2385 WZ 4003 Specific dual inhibitor of NUAK1 (ARK5) and NUAK2 (SNARK) €80.00
2452 VE 822 Selective ATR inhibitor that decreases survival of pancreatic cancer cells €110.00
1893 VE 821 Inhibitor of the DNA damage response kinase ATR €80.00
2418 UNC 0379 Substrate competitive inhibitor of the H4K20 HMTase SETD8 €125.00
3402 THZ531 First-in-class, potent, selective, covalent CDK12/CDK13 inhibitor €130.00
2339 TH 1834 Tip60 histone acetyltransferase inhibitor €135.00
2249 Tenovin 6 Small water soluble p53 activator and SIRT inhibitor €105.00
3184 SR-4835 Potent, highly selective and orally bioavailable dual CDK12/CDK13 inhibitor €130.00
2365 SR 3576 Very potent JNK3 inhibitor with >2800-fold selectivity over p38 €135.00
2512 Spautin 1 Inhibitor of USP10 and USP13 and Beclin1 related autophagy €95.00
2519 SP 600125 Selective, reversible, and ATP-competitive JNK inhibitor €70.00
2437 SP 141 Specific MDM2 inhibitor with therapeutic effects in breast cancer models €120.00
1614 SNS 032 CDK inhibitor (2, 7 and 9 specific) €85.00
2164 SJ 172550 Small molecule inhibitor of MDMX €95.00

Items 1 to 15 of 72 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Please wait...